Analyst Ratings For American Renal Associates Holdings Inc (NYSE:ARA)
Today, Barclays initiated coverage on American Renal Associates Holdings Inc (NYSE:ARA) with a Equal Weight.
There are 3 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on American Renal Associates Holdings Inc (NYSE:ARA) is Buy with a consensus target price of $22.75 per share, a potential 44.90% upside.
Some recent analyst ratings include
- 12/14/2018-American Renal Associates Holdings Inc (NYSE:ARA) has coverage initiated with a Equal Weight rating
- 8/23/2018-American Renal Associates Holdings Inc (NYSE:ARA) gets upgraded to Outperform by Leerink Swann with a price target of $26.00
- 8/9/2018-American Renal Associates Holdings Inc (NYSE:ARA) had its Buy rating reiterated by SunTrust Banks with a $25.00 price target
- 7/19/2018-American Renal Associates Holdings Inc (NYSE:ARA) has coverage initiated with a Neutral rating and $16.00 price target
- 5/11/2017-American Renal Associates Holdings Inc (NYSE:ARA) gets upgraded to Outperform by Wells Fargo & Co
- On 6/9/2017 Jason Allen Ross Brewster, Director, bought 80,000 with an average share price of $0.03 per share and the total transaction amounting to $2,400.00.
- On 4/26/2016 John J Mcdonough, COO, bought 1,000 with an average share price of $22.00 per share and the total transaction amounting to $22,000.00.
- On 4/26/2016 Jonathan L Wilcox, CFO, bought 500 with an average share price of $22.00 per share and the total transaction amounting to $11,000.00.
- On 4/26/2016 Michael Ray Costa, VP, bought 370 with an average share price of $22.00 per share and the total transaction amounting to $8,140.00.
- On 4/2/2015 Meyer (Mike) Frederi Florence, Director, bought 12,000 with an average share price of $0.01 per share and the total transaction amounting to $120.00.
About American Renal Associates Holdings Inc (NYSE:ARA)
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of June 30, 2018, it owned and operated 233 dialysis clinics in partnership with 400 nephrologist partners treating approximately 16,000 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.
Recent Trading Activity for American Renal Associates Holdings Inc (NYSE:ARA)
Shares of American Renal Associates Holdings Inc closed the previous trading session at 15,70 −0,33 2,06 % with 15.61 shares trading hands.